GAP43 and primary progressive multiple sclerosis: Low GAP-43 levels in cerebrospinal fluid were associated with a poorer response to treatment of primary progressive multiple sclerosis using fingolimod or alemtuzumab (Sandelius et al., 2019) suggesting that GAP-43 is important in mediating its therapeutic effects.